Trial record 14 of 864 for:    Open Studies | "Stem Cell Transplantation"

Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2011 by King Faisal Specialist Hospital & Research Center
Sponsor:
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT00531583
First received: September 17, 2007
Last updated: December 11, 2011
Last verified: December 2011
  Purpose

Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation program for pts w/AML in 1st & 2nd complete remission w/no HLA matched related donor


Condition Intervention
Leukemia, Monocytic, Acute
Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor

Resource links provided by NLM:


Further study details as provided by King Faisal Specialist Hospital & Research Center:

Primary Outcome Measures:
  • Efficacy [ Time Frame: 2009-2015 ] [ Designated as safety issue: No ]

Estimated Enrollment: 350
Study Start Date: March 2001
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation
    Autologous PBSCT
  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with AML in 1st & 2nd complete remission w/no HLA matched related donor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00531583

Contacts
Contact: Fahad AlMohareb, MD fmohareb@kfshrc.edu.sa

Locations
Saudi Arabia
KFSH&RC Recruiting
Riyadh, Saudi Arabia, 1211
Contact: Fahad AlMohareb, MD         
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Fahad AlMohareb KFSH&RC
  More Information

No publications provided

Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT00531583     History of Changes
Other Study ID Numbers: RAC#2001-004
Study First Received: September 17, 2007
Last Updated: December 11, 2011
Health Authority: ORA: KFSH&RC, Riyadh, Saudi Arabia

Keywords provided by King Faisal Specialist Hospital & Research Center:
AML in 1st & 2nd complete remission w/no HLA matched related donor

Additional relevant MeSH terms:
Leukemia
Leukemia, Monocytic, Acute
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid, Acute
Leukemia, Myeloid

ClinicalTrials.gov processed this record on July 26, 2014